Types of tea and ways of its application
Tea – a drink for all seasons. But tea is used not only in food industry but also in cosmetics and in the treatment of various medical problems. There are…

Continue reading →

Traditional recipes of beauty for healthy hair
Every woman knows the beauty secrets of your hair and skillfully uses them. I would like to share a few beauty secrets healthy and beautiful hair. In addition to regular…

Continue reading →

Plants of the Orenburg region against infections
World's first OSU scientists suggested to create antibacterial drugs from medicinal plants against the chemical communication between organisms. The project of Anna Tolmacheva "Resource potential of medicinal plants of the…

Continue reading →

A set of exercises exercise therapy for chronic hepatitis

“Gilead” has signed a licensing agreement with the Indian manufacturers

On 15 September it was announced that the company “Gilead” has signed a licensing agreement with seven Indian companies for the rights to produce and sell drugs sofosbuvir (“Cavaldi”) and ledipasvir for the treatment of viral hepatitis C in the territory of certain countries.

Under the agreement, the licensees will be able to supply sofosbuvir and combination drug ledipasvir/sofosbuvir in 91 markets of countries with low and middle income countries. According to preliminary data, the price for a three-month course of treatment with sofosbuvir should be around 900 USD.

According ITPCru, in the region of Eastern Europe and Central Asia the license applies only to Tajikistan, Turkmenistan, Uzbekistan and Kyrgyzstan. Russia, Ukraine, Georgia and Moldova are not included in the territory of the license.

Experts in the field of health and representatives of civil society accused of “Gilead” in that the company’s policy, oriented solely to obtain commercial gain, blocking access to the drug. Even in developed countries cannot afford to provide the drug to all those in need because of overly high prices, reaching 84000. According to some studies, the cost of production of a three-month course sofoluwe is only about 70 dollars.

Earlier, on 10 February 2014 the company Gilead has applied to the FDA food and drug administration (FDA) for registration of combination drug ledipasvir/sofosbuvir (LDV/SOF) for the treatment of viral hepatitis C and had intended to apply for registration in other countries. And in October the us FDA approved combination drug Harvoni for the treatment of viral hepatitis C with a regime of taking one tablet a day. The Committee for medicinal products for medical use European medicines Agency (EMA) also recommended for approval in the EU this drug. Harvoni will be the first combination drug for the treatment of hepatitis C in the world market. This drug is indicated for the treatment of viral hepatitis C genotype 1 in adults for 8 or 12 weeks (depending on the experience of the previous treatment and presence of cirrhosis) without having to add the current standard treatment is interferon and ribavirin. Oral drug Harvoni Gilead Sciences for once daily use contains 90 mg ladieswear and 400 mg sofoluwe. Sofosbuvir is a NS5B polymerase inhibitor of hepatitis C virus, ledipasvir – NS5A inhibitor protein, the main component of the replication complex of the virus. Clinical trials of the drug showed that the application of the combination of sofosbuvir + ledipasvir allows to obtain a sustained virologic response in 94-99% patients. The treatment is well tolerated by most patients. Widespread use of the drug may halt the epidemic of viral hepatitis C.

Herbs for hair loss
The problem of thinning and loss of hair at all times was and remains most relevant. Falls daily about 100 hairs and this phenomenon is considered normal. People with a…

...

Folk medicine, herbal treatment
We will tell You about the so-called non-traditional, folk medicine, proven by many generations of our ancestors. For millennia, these recipes are changed, perfected, and saved many, many lives, because…

...